In this section

ICR publications

ICR ImmNet publications feed

Browse all ICR publications

ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.

01 July 2026
The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.

01 July 2026
Expanding the human proteome with microproteins and peptideins.

18 June 2026
Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.

15 June 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

05 June 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

05 June 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

05 June 2026
Author Correction: Community benchmarking and evaluation of human unannotated microprotein detection by mass spectrometry based proteomics.

02 June 2026
The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.

01 June 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study.

31 May 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

22 May 2026
Somatic evolution following cancer treatment in normal tissue.

21 May 2026